1-3 of 3
Rachid C. Baz, MD
Close
Sort by
Journal Articles

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Michel Delforge, MDPhD, Rachid C. Baz, MD, Michele Cavo, Natalie S. Callander, MD, Armin Ghobadi, MD, Paula Rodriguez-Otero, MD PhD, María-Victoria Mateos, MD PhD, Monica Massaro, MPH, Li Ding, Payal Patel, Gianfranco Pittari, MD PhD, Steven Novick, MDPhD, Sergio A. Giralt, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-137156
Published: 2020
Journal Articles

Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Shaji K. Kumar, MD, Rachid C. Baz, MD, Robert Z. Orlowski, MDPhD, Larry D. Anderson, Jr., MD PhD, Hong Ma, MD, Alexandria Shrewsbury, MS, Katrina A. Croghan, M.S., Mrinalini Bilgi, MS, Ankit Kansagra, MD, Prashant Kapoor, MD, Zonghai Li, MD PhD, Jason Brayer, PhDMD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-139802
Published: 2020
Journal Articles

Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.

Toni K. Choueiri, MD, Esteban Walker, PhD, Rachid C. Baz, MD, Rony M. Abou-Jawde, MD, Snehal G. Thakkar, MD, Bridget McGowan, Megan Kelly, Steven Andresen, MD, Mohamad Hussein, MD
Journal: Blood
Blood (2005) 106 (11): 5155.
https://doi.org/10.1182/blood.V106.11.5155.5155
Published: 2005